<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04922554</url>
  </required_header>
  <id_info>
    <org_study_id>PTK0796-NTM-20203</org_study_id>
    <nct_id>NCT04922554</nct_id>
  </id_info>
  <brief_title>Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)</brief_title>
  <official_title>A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, &amp; Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paratek Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Paratek Pharmaceuticals Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety and tolerability of oral&#xD;
      omadacycline as compared to placebo in the treatment of adults with Nontuberculous&#xD;
      Mycobacterial (NTM) pulmonary disease caused by Mycobacterium abscessus complex (MABc)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total duration of subject participation in the study is approximately 5 months which&#xD;
      includes a total duration of study treatment for approximately 3 months (84 days). Eligible&#xD;
      participants will be randomized 1.5:1 to receive 3 months of treatment with either&#xD;
      omadacycline or placebo (monotherapy). The study will use a double-dummy design in order to&#xD;
      maintain the study blinding.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response on NTM Symptom Assessment Scale at Day 84</measure>
    <time_frame>Day 1 to Day 84/EOT</time_frame>
    <description>Improvement in severity of at least 50% of symptoms present at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reported adverse events (AEs)</measure>
    <time_frame>Day 1 to Day 84/EOT</time_frame>
    <description>To assess reported adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in laboratory tests</measure>
    <time_frame>Day 1 to Day 84/EOT</time_frame>
    <description>To assess the incidents of abnormal hematology, biochemistry, coagulation and urinalysis assessments following 84 days of IP administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant (CS), outside normal range laboratory tests</measure>
    <time_frame>Day 1 to Day 84/EOT</time_frame>
    <description>To assess the incidents of CS abnormal hematology, biochemistry, coagulation and urinalysis assessments following 84 days of IP administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in vital signs</measure>
    <time_frame>Day 1 to Day 84/EOT</time_frame>
    <description>To assess the incidents of abnormal heart rate and blood pressure assessments following 84 days of IP administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant (CS) vital signs</measure>
    <time_frame>Day 1 to Day 84/EOT</time_frame>
    <description>To assess the incidents of CS heart rate and blood pressure following 84 days of IP administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in electrocardiogram (ECG)</measure>
    <time_frame>Day 1 to Day 84/EOT</time_frame>
    <description>To assess the incidents of abnormal heart rate, cardiac rhythm, PR interval, RR interval, QRS interval, QT interval and QTc interval assessments following 84 days of IP administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant (CS) electrocardiogram (ECG) findings</measure>
    <time_frame>Day 1 to Day 84/EOT</time_frame>
    <description>To assess the incidents of CS and QTc interval assessments following 84 days of IP administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the total score of the Quality of Life - Bronchiectasis (QOL-B) questionnaire</measure>
    <time_frame>Day 1 to Day 84/EOT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in global score and individual domain scores of the St. George Respiratory Questionnaire (SGRQ)</measure>
    <time_frame>Day 1 to Day 84/EOT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient-Reported Outcomes Measurement Information System Short Form v1.0 - Fatigue 7a Daily (PROMIS-7a)</measure>
    <time_frame>Day 1 to Day 84/EOT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient Clinical Impression of Severity (PGI-S)</measure>
    <time_frame>Day 1 to Day 84/EOT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient Clinical Impression of Change (PGI-C)</measure>
    <time_frame>Day 1 to Day 84/EOT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Global Impression - Severity of Illness (CGI-S)</measure>
    <time_frame>Day 1 to Day 84/EOT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Global Impression - Improvement (CGI-I)</measure>
    <time_frame>Day 1 to Day 84/EOT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients reporting no new symptoms with a severity worse than mild on the NTM Symptom Assessment Questionnaire</measure>
    <time_frame>Day 1 to Day 84/EOT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in quantitative sputum culture at Day 84</measure>
    <time_frame>Day 1 to Day 84/EOT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to growth in liquid medium only</measure>
    <time_frame>Day 1 to Day 84/EOT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first negative sputum culture</measure>
    <time_frame>Day 1 to Day 84/EOT</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Mycobacterium Infections, Nontuberculous</condition>
  <condition>Mycobacterium Abscessus Infection</condition>
  <condition>Nontuberculous Mycobacterial Lung Disease</condition>
  <condition>Nontuberculous Mycobacterial Pulmonary Infection</condition>
  <arm_group>
    <arm_group_label>Omadacycline 300 mg PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omadacycline 150 mg tablets (x 2) administered orally, once daily, q24h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo PO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets resembling omadacycline (x 2) administered once daily, q24h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omadacycline Oral Tablet</intervention_name>
    <description>omadacycline 300 mg orally, once daily (150 mg tablets x 2)</description>
    <arm_group_label>Omadacycline 300 mg PO</arm_group_label>
    <other_name>Nuzyra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo tablets resembling omadacycline orally, once daily (x 2 tablets)</description>
    <arm_group_label>Placebo PO</arm_group_label>
    <other_name>placebo tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Has a diagnosis of Nontuberculous Mycobacterial pulmonary disease caused by MABc&#xD;
&#xD;
          -  Has at least 2 of the following NTM-infection symptoms present at Screening and&#xD;
             Baseline: chronic cough, coughing up blood (hemoptysis), wheezing, chest pain,&#xD;
             frequent throat clearing, phlegm or sputum production, shortness of breath, fatigue,&#xD;
             fever, night sweats, poor appetite, and/or weight loss.&#xD;
&#xD;
          -  At least 1 positive pulmonary (sputum) culture for MABc in the 6 months prior to&#xD;
             Screening and 1 positive culture at Screening&#xD;
&#xD;
          -  Radiographic evidence of MABc infection via computed tomography (CT) scan of the chest&#xD;
             within 3 months prior to Screening&#xD;
&#xD;
          -  In the opinion of the investigator, guideline-directed antibiotic therapy for&#xD;
             treatment of MABc will not be required within the next 3 months, and a delay, in order&#xD;
             for the subject to participate in a placebo-controlled clinical trial, is considered&#xD;
             reasonable and clinically acceptable&#xD;
&#xD;
          -  Additional inclusion criteria as per protocol&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Has received antibiotic treatment within 6 months prior to Screening for MABc or MAC&#xD;
&#xD;
          -  Has received systemic or inhaled antibiotic therapy (other than chronic macrolide&#xD;
             therapy) within 4 weeks prior to Screening&#xD;
&#xD;
          -  Has any of the following medical conditions:&#xD;
&#xD;
          -  Active pulmonary malignancy, or any type of malignancy requiring chemotherapy or&#xD;
             radiation within 1 year prior to Screening&#xD;
&#xD;
          -  Active allergic bronchopulmonary mycosis, or any other condition requiring chronic&#xD;
             treatment with systemic corticosteroids within 90 days prior to Screening&#xD;
&#xD;
          -  Radiologic evidence of cavitary disease&#xD;
&#xD;
          -  Known active pulmonary tuberculosis&#xD;
&#xD;
          -  Cystic fibrosis&#xD;
&#xD;
          -  History of lung transplantation&#xD;
&#xD;
          -  Another advanced lung disease with a known percent predicted forced expiratory volume&#xD;
             in 1 second &lt; 30%.&#xD;
&#xD;
          -  Disseminated or extra-pulmonary NTM disease&#xD;
&#xD;
          -  Has been previously treated with omadacycline&#xD;
&#xD;
          -  Has a history of hypersensitivity or allergic reaction to tetracyclines&#xD;
&#xD;
          -  Additional exclusion criteria as per protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Berman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Paratek Pharmaceuticals Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alissa Sirbu</last_name>
    <phone>617.459.5307</phone>
    <email>alissa.sirbu@paratekpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Manley</last_name>
    <phone>484.682.4976</phone>
    <email>amy.manley@paratekpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amen Hamed</last_name>
      <phone>202-444-0895</phone>
      <email>amen.m.hamed@gunet.georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Anne O'Donnell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Florida Pulmonary Group</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Summo</last_name>
      <phone>407-841-1100</phone>
      <phone_ext>225</phone_ext>
      <email>ksummo@cfpulmonary.com</email>
    </contact>
    <investigator>
      <last_name>Tabarak Qureshi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Francis Medical Institute</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis J Averill, MD</last_name>
      <phone>727-210-4606</phone>
      <email>faverillresearch@stfrancismed.com</email>
    </contact>
    <investigator>
      <last_name>Francis J Averill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Montera</last_name>
      <phone>813-844-7948</phone>
      <email>bmontera@usf.edu</email>
    </contact>
    <investigator>
      <last_name>Chakrapol Sriaroon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Richmond</last_name>
      <phone>314-454-0058</phone>
      <email>cmrichmond@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Andrej Spec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aboubacar Cherif</last_name>
      <phone>603-650-2392</phone>
      <email>Aboubacar.cherif@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Talbot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pulmonary Health Physicians, PC</name>
      <address>
        <city>Liverpool</city>
        <state>New York</state>
        <zip>13088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannine Moore</last_name>
      <phone>315-234-0823</phone>
      <email>Jeannine.Moore@CNYLungs.com</email>
    </contact>
    <investigator>
      <last_name>Sherif El Bayadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeastern Research Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mccutcheon</last_name>
      <phone>336-659-8414</phone>
      <email>kmccutcheon@southeasternresearchcenter.com</email>
    </contact>
    <investigator>
      <last_name>Reginald Fowler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ted Warnock, BS</last_name>
      <phone>503-494-8121</phone>
      <email>warnockt@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Winthrop, MPH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebekah Hibbard, BS, CCRC</last_name>
      <phone>903-877-8246</phone>
      <email>rebekah.hibbard@uthct.edu</email>
    </contact>
    <investigator>
      <last_name>Julie Philley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nontuberculous Mycobacteria (NTM)</keyword>
  <keyword>Mycobacterium abscessus complex (MABc)</keyword>
  <keyword>NTM pulmonary disease</keyword>
  <keyword>NTM lung disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium Infections, Nontuberculous</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

